So for this private sale of stocks to institutions, I would think the price would be around the buying price. What is the reason for it to rise .51 so far. I'm not complaining about that though. Would be nice if it hits mid $7's again.
1. It was trading between 8-10 before its first rejection by FDA
2. It's trading at 6 after pending FDA approval and already approvals in Europe
3. It secured private investment for marketing and sales
4. FDA news is coming out soon